Abstract
Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Current Alzheimer Research
Title:Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Volume: 14 Issue: 9
Author(s): Stephen M. Meyer, Kristina A. Bertzos, Magdalena Perez, Donald J. Connor*, Kimberly Schafer and Sarah Walter
Affiliation:
- Consultants in Cognitive and Clinical Trials,United States
Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Abstract: Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Export Options
About this article
Cite this article as:
Meyer M. Stephen , Bertzos A. Kristina , Perez Magdalena , Connor J. Donald*, Schafer Kimberly and Walter Sarah , Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions, Current Alzheimer Research 2017; 14 (9) . https://dx.doi.org/10.2174/1567205014666170417122744
DOI https://dx.doi.org/10.2174/1567205014666170417122744 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Future of Alzheimer's Therapy with the Best Approach
CNS & Neurological Disorders - Drug Targets Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design Adrenomedullin Expression in Alzheimer's Brain
Current Alzheimer Research Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design The Cytokine Network in HIV Infection
Current Molecular Medicine AMPK Function in Aging Process
Current Drug Targets The Effect of Cyberspace-Based Education on the Well-Being of Caregivers of Elderly People with Dementia
Current Aging Science Development of Novel Amyloid Imaging Agents Based Upon Thioflavin S
Current Alzheimer Research Subject Index to Volume 1
Current Vascular Pharmacology The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical Biotechnology Chemical and Molecular Aspects on Interactions of Galanthamine and Its Derivatives with Cholinesterases
Current Pharmaceutical Biotechnology Oleanolic Acid Ameliorates Aβ25-35 Injection-induced Memory Deficit in Alzheimer’s Disease Model Rats by Maintaining Synaptic Plasticity
CNS & Neurological Disorders - Drug Targets miR-132 Down-regulates Methyl CpG Binding Protein 2 (MeCP2) During Cognitive Dysfunction Following Chronic Cerebral Hypoperfusion
Current Neurovascular Research D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Preventive Antidepressant use in Patients with Hepatitis C Treated with Interferon-Alfa: a Systematic Review
Current Psychiatry Reviews Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update
Vascular Disease Prevention (Discontinued) GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) 3D MI-DRAGON: New Model for the Reconstruction of US FDA Drug- Target Network and Theoretical-Experimental Studies of Inhibitors of Rasagiline Derivatives for AChE
Current Topics in Medicinal Chemistry REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets